Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ReShape Lifesciences Inc

< Previous 1 2 Next >
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Participate in Investor and Industry Conferences in June
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences Announces Formation of International Scientific Advisory Board
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences Announces $750,000 Registered Direct Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences to Present at the Q4 Investor Summit
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.